Invest Securities confirms its Buy rating on Transgene shares, with a price target reduced from 5.7 to 5.4 euros.

The research firm reports that the company has presented a 2023 plan with several catalysts that should reinforce the first results announced in most of their clinical programs.

In particular, two clinical trials potentially paving the way to registration are planned in the short term in the therapeutic vaccine franchise.

2023 should be a year of consolidation, while 2024 should be the year of proof of concept", says the analyst.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.